Transforming brain health through earlier detection — delivered where care happens.

We build the diagnostic infrastructure that brings cognitive disease detection earlier, closer to patients, and into the hands of clinicians who can act on it.​

 — OUR MISSION — 

 

 To change the trajectory of brain disease by making early, accurate diagnosis routine, actionable, and accessible — through connected telehealth care, retinal imaging, and blood-based biomarkers that work together across the full patient journey. 

 — THE PROBLEM WE'RE SOLVING — 

 

Brain disease advances years before a patient ever walks into a clinic. 

 75%

 Of dementia cases are undiagnosed or diagnosed only after significant irreversible decline has already occurred — a window where early intervention could change everything. 

Years-long diagnostic delays push patients past the window for therapeutic benefit from emerging treatments targeting amyloid pathology.
PCPs lack specialist bandwidth — neurology wait times of 6–12+ months are common, and most primary care offices have no clear cognitive referral pathway.
Biomarker access is fragmented — pTau-217, NfL, and retinal imaging exist, but no integrated platform makes them actionable at the point of primary care.

 — INTEGRATED PLATFORMS — 

 

One continuum from first concern to clinical action. 

Each platform closes a key gap in the cognitive care journey:
access, detection, and scalable diagnostics. 

TELEHEALTH CARE
BrainHealth Clinic Logo_Vertical_Color_331

BrainHealth Clinic™

BrainHealth Clinic is a comprehensive cognitive care telehealth platform that manages the full patient journey — from first concern through ongoing treatment and support. We handle assessment, imaging and biomarker testing, neurology access, patient and caregiver engagement, and longitudinal management so patients receive specialized cognitive care without gaps or delays.
  • Fast referral outreach and scheduling
  • Full cognitive assessment, imaging, and biomarker testing
  • Neurology consultation in weeks, not months
RETINAL IMAGING
retina (002)

Afina™ Retinal Imaging*

A cloud-based AI imaging pathway designed to identify retinal signatures associated with neurodegenerative disease and treatment safety monitoring.

  • Non-invasive scan performed in minutes
  • AI-enabled analysis for disease signatures
  • Research and validation with leading partners

 

BLOOD BIOMARKERS
biomarker-1

Duritect™ 

Duritect™ , developed by Durin Life Sciences, and recently acquired by NeuroVision, is a diagnostics platform designed to support earlier detection and longitudinal monitoring of neurodegenerative diseases.
  • Programs in development include: Alzheimer’s, Parkinson’s disease, and ALS
  • Designed for real-world clinical deployment*
  • Part of NeuroVision’s integrated BrainHealth Platform

 *Certain components of the platform are under development or investigational and are not currently FDA-cleared or approved. 

 — THE SCIENCE — 

 

Diagnostics plus care delivery — not diagnostics in isolation. 

NeuroVision's advantage is the ability to connect emerging diagnostic tools with clinical workflows that can actually reach patients: primary care identification, teleneurology access, biomarker interpretation, and longitudinal engagement. 

ACCESS
Designed for primary care and health-system workflows.
ACTION
Testing connected to consults, care plans, and next steps
SCALE
Telehealth infrastructure for broad deployment.
DATA
Multi-modal insights across cognition, biomarkers, imaging, and longitudinal care.

 — INVESTORS — 

 

Capital aligned with a mission that matters 

We are venture backed by financial and strategic investors who share our vision to transform neuroscience and access pathways for patients. 

 — BOARD OF DIRECTORS — 

 

Experience at the intersection of medicine, science, and scale. 

Our board brings together distinguished leaders across healthcare, science, finance, and business to help guide NeuroVision’s strategic growth, innovation initiatives, and mission to advance brain health through earlier detection and longitudinal care.

Rene Chaze

RENÉ CHAZE

DIRECTOR

Learn more

René Chaze is a strategy, operations, and finance executive with 35+ years of leadership experience spanning family office investing, private equity portfolio companies, financial services, and consulting. As a Partner at Tiny Orange Capital, he focuses primarily on high-growth technology sectors including blockchain, digital assets, and life sciences. René previously held senior leadership roles at Edelman Financial Services, including CFO, COO, and Head of M&A. Earlier in his career, he was a Partner at Ernst & Young, where he advised telecom, media and technology clients on tax strategy, structuring, and policy. 

Ric Edelman

RIC EDELMAN

DIRECTOR

Learn more

Ric Edelman founded the nation's largest financial planning firm, which manages $350 billion for 1.4 million families across the United States. He was ranked three times as the nation's #1 Independent Financial Advisor by Barron's, is in two industry Halls of Fame and recipient of three Lifetime Achievement Awards. He holds two patents for financial product innovation, appeared on The Oprah Winfrey Show five times and was once the answer to 21 Across in a New York Times crossword puzzle.

Edelman is the #1 bestselling author of 14 books on personal finance, with more than 1.2 million copies in eight languages worldwide. At Rowan University, he is Founding Head of the School of Financial Planning; benefactor of Edelman Fossil Park, the Edelman Planetarium and the Edelman Scholars; and the Ric Edelman College of Communications, Humanities and Social Sciences is named in his honor.

len potter

LEN POTTER

DIRECTOR

Learn more

Leonard A. Potter founded Wildcat Capital Management in 2011 and has served since then as its president and chief investment officer. Mr. Potter also serves as Chairman of Infinity Q Capital Management and as a Senior Managing Director of Vida Ventures, each a fund investment manager. From 2002 through 2009, Mr. Potter was managing director—private equity at Soros Fund Management LLC (“SFM”) where, from May 2005 through July 2009, he served as co-head of its private equity group and as a member of the private equity investment committee. Mr. Potter has served and continues to serve as a director on a number of boards of public and private companies, including Hilton Grand Vacations (NYSE: HGV), Solar Capital Ltd. (NASDAQ: SLRC), Solar Senior Capital Ltd. (NASDAQ: SUNS) and SuRo Capital Corporation (NASDAQ: SSSS).

mark selna

MARK SELNA, MD

DIRECTOR

Learn more

With over 30 years' experience in health system and health plan leadership, as well as in medical practice, Dr. Selna most recently served as President and CEO of Quartz. He is also co-founder of an AI company using data and algorithms to help health systems improve financial, operational, and clinical outcomes.

RoyTwyman_Photo-1

ROY TWYMAN, MD

DIRECTOR

Learn more

Roy Ervin Twyman, MD, has nearly 20 years' experience in neuroscience pharmaceutical drug development, most recently as senior vice president at Janssen Pharmaceutical Research & Development LLC, where he was the Alzheimer's disease area leader in the Neuroscience Therapeutic Area. Dr. Twyman has served on advisory committees and panels of the U.S. Food and Drug Administration and the Institute of Medicine.  Board-certified in psychiatry and neurology, Dr. Twyman was an academic neurologist and has written chapters in several books and published numerous articles in peer-reviewed medical and scientific journals.

Steve Verdooner3

STEVEN VERDOONER

CEO, DIRECTOR, & CO-FOUNDER 

Learn more

Steve is a seasoned, results-driven executive with over 30 years of experience in the ophthalmology, neurology and medical device markets, with a proven track record of launching and leading successful startup businesses. He has expertise in a diverse range of business management including sales and marketing, research and development, operations and regulatory management, brand management, business development and strategic planning. Steve has a proven ability to lead and interface with key opinion leaders, advisory boards, customers, scientists, engineers, Company Boards and the financial community.

Steve serves as the CEO of NeuroVision Imaging, a company developing retinal and fluid biomarkers for neurodegenerative disease. Steve was co-founder and CEO of Ophthalmic Imaging Systems (1984-2007). OIS was a company dedicated to research, development, marketing, selling and manufacturing diagnostic medical imaging systems and informatics software for the eye care market. Steve led the initial research, market analysis, product development, commercialization strategy, and product launch for a revolutionary new imaging system that was the first of its kind in ophthalmology. Steve was involved in establishing and building the company infrastructure that took OIS to a public offering in 1992 and eventually being sold to Merge Healthcare in 2011. Steve next joined OPKO Health, Inc. as Executive Vice President. OPKO is a publicly traded specialty healthcare company (that engages in the discovery, development, and commercialization of pharmaceutical products, medical devices, vaccines, and diagnostic technologies.

Glenn Walthall

GLENN WALTHALL

DIRECTOR

Learn more

Glenn serves as Gaston Capital’s Managing Partner. His career spans thirty years as a venture capitalist, investment banker, bank executive and consultant. Glenn is currently the Chairman of Bold Therapeutics, and Intezyne Technologies, and a board member of Enviro-Master International, SMRxT, and Mobility Designed.  He resides in Charlotte (NC), and has a BS and MBA from Virginia Tech. 

 — PARTNERSHIPS & AFFILIATIONS — 

 

Built on trust with the institutions defining cognitive care. 

NeuroVision works alongside leading academic medical centers, research institutions, and industry partners to advance the science and delivery of early cognitive disease detection.